These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 38615361)

  • 1. Adaptive promising zone design for cancer immunotherapy with heterogeneous delayed treatment effect.
    Li B; Yan F; Jiang D
    J Biopharm Stat; 2024 Apr; ():1-20. PubMed ID: 38615361
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A group sequential design and sample size estimation for an immunotherapy trial with a delayed treatment effect.
    Li B; Su L; Gao J; Jiang L; Yan F
    Stat Methods Med Res; 2021 Mar; 30(3):904-915. PubMed ID: 33357047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Group sequential designs for cancer immunotherapy trial with delayed treatment effect.
    Wu J; Li Y; Zhu L
    J Biopharm Stat; 2024 Jan; 34(1):1-15. PubMed ID: 36740768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sample size adjustment designs with time-to-event outcomes: A caution.
    Freidlin B; Korn EL
    Clin Trials; 2017 Dec; 14(6):597-604. PubMed ID: 28795844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Group sequential design with maximin efficiency robust test for immunotherapy with generalized delayed treatment effect.
    Li B; Zhang J; Yang W; Su L; Yan F
    Pharm Stat; 2024; 23(1):107-133. PubMed ID: 37859531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sequential monitoring of cancer immunotherapy trial with random delayed treatment effect.
    Wu J; Zhu L; Li Y
    J Biopharm Stat; 2023 Dec; ():1-14. PubMed ID: 38146192
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sample size adjustment based on promising interim results and its application in confirmatory clinical trials.
    Chen YH; Li C; Lan KK
    Clin Trials; 2015 Dec; 12(6):584-95. PubMed ID: 26195615
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer immunotherapy trial design with delayed treatment effect.
    Wu J; Wei J
    Pharm Stat; 2020 May; 19(3):202-213. PubMed ID: 31729149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adaptive group sequential survival comparisons based on log-rank and pointwise test statistics.
    Feld J; Faldum A; Schmidt R
    Stat Methods Med Res; 2021 Dec; 30(12):2562-2581. PubMed ID: 34641702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Statistical inference following sample size adjustment based on the 50%-conditional-power principle.
    Chen YHJ; Yuan SS; Li X
    J Biopharm Stat; 2018; 28(3):575-587. PubMed ID: 28850000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. M&M: A maximum duration design with the Maxcombo test for a group sequential trial of an immunotherapy with a random delayed treatment effect.
    Li B; Su L; Ye Y; Yan F
    Stat Med; 2022 Feb; 41(4):815-830. PubMed ID: 34783047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Study design of single-arm phase II immunotherapy trials with long-term survivors and random delayed treatment effect.
    Chu C; Liu S; Rong A
    Pharm Stat; 2020 Jul; 19(4):358-369. PubMed ID: 31930622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer immunotherapy trial design with random delayed treatment effect and cure rate.
    Wu J; Wei J
    Stat Med; 2022 Feb; 41(4):786-797. PubMed ID: 34779534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer immunotherapy trial design with cure rate and delayed treatment effect.
    Wei J; Wu J
    Stat Med; 2020 Mar; 39(6):698-708. PubMed ID: 31773770
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimal promising zone designs.
    Hsiao ST; Liu L; Mehta CR
    Biom J; 2019 Sep; 61(5):1175-1186. PubMed ID: 30411405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increasing the sample size when the unblinded interim result is promising.
    Chen YH; DeMets DL; Lan KK
    Stat Med; 2004 Apr; 23(7):1023-38. PubMed ID: 15057876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimal adaptive promising zone designs.
    Mehta C; Bhingare A; Liu L; Senchaudhuri P
    Stat Med; 2022 May; 41(11):1950-1970. PubMed ID: 35165917
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adaptive sample size modification in clinical trials: start small then ask for more?
    Jennison C; Turnbull BW
    Stat Med; 2015 Dec; 34(29):3793-810. PubMed ID: 26172385
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methods for flexible sample-size design in clinical trials: Likelihood, weighted, dual test, and promising zone approaches.
    Shih WJ; Li G; Wang Y
    Contemp Clin Trials; 2016 Mar; 47():40-8. PubMed ID: 26674739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Designing cancer immunotherapy trials with delayed treatment effect using maximin efficiency robust statistics.
    Ding X; Wu J
    Pharm Stat; 2020 Jul; 19(4):424-435. PubMed ID: 32090453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.